Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on PTC Therapeutics, maintaining a $64 price target.
September 17, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on PTC Therapeutics, maintaining a $64 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $64 price target by a reputable analyst suggests positive sentiment and potential upside for PTC Therapeutics. This could lead to increased investor confidence and buying interest in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100